about
Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritisValidity and reliability of patient reported outcomes used in psoriasis: results from two randomized clinical trialsCD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureyleneCollecting a set of psoriasis family material through a patient organisation; clinical characterisation and presence of additional disorders.Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)/Childhood Health Assessment Questionnaire (C-Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and quality-of-life instruments 1985-2010.Acupuncture for psoriasis: protocol for a systematic reviewUVB phototherapy in an outpatient setting or at home: a pragmatic randomised single-blind trial designed to settle the discussion. The PLUTO study.Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.Mutation analysis of the LCE3B/LCE3C genes in Psoriasis.Narrowband ultraviolet B light treatment changes plasma concentrations of MMP-3, MMP-9 and TIMP-3 in psoriatic patients.Cognitive impairment in patients with severe psoriasisEfficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phasEvaluation of fatigue and its correlation with quality of life index, anxiety symptoms, depression and activity of disease in patients with psoriatic arthritis.Evaluating Dosage Optimality for Tofacitinib, an Oral Janus Kinase Inhibitor, in Plaque Psoriasis, and the Influence of Body WeightEfficacy and Safety of Efalizumab in Patients with Moderate-to-Severe Plaque Psoriasis Resistant to Previous Anti-Psoriatic Treatment: Results of a Multicentre, Open-label, Phase IIIb/IV Trial.Patient considerations and targeted therapies in the management of psoriasis in Chinese patients: role of ustekinumab.Cost effectiveness of home ultraviolet B phototherapy for psoriasis: economic evaluation of a randomised controlled trial (PLUTO study).The association between 38 previously reported polymorphisms and psoriasis in a Polish population: High predicative accuracy of a genetic risk score combining 16 loci.Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis.Moesin and stress-induced phosphoprotein-1 are possible sero-diagnostic markers of psoriasis.Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis.Interleukin-11 therapy selectively downregulates type I cytokine proinflammatory pathways in psoriasis lesions.The GOLMePsA study protocol: an investigator-initiated, double-blind, parallel-group, randomised, controlled trial of GOLimumab and methotrexate versus methotrexate in early diagnosed psoriatic arthritis using clinical and whole body MRI outcomesSerum Angiotensin converting enzyme in pemphigus vulgaris.In psoriasis, levels of hope and quality of life are linked.Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.Comorbidities and cardiovascular risk factors in patients with psoriasis.Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion.Predictors of functional deterioration in Chinese patients with psoriatic arthritis: a longitudinal studySynthetic retinoids in dermatology.Metabolic syndrome and its components in patients with psoriasis.Discriminant validity, responsiveness and reliability of the arthritis-specific Work Productivity Survey assessing workplace and household productivity in patients with psoriatic arthritisTumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitorsSpondyloarthritides: evolving therapiesNovel topical therapy for mild-to-moderate plaque psoriasis: focus on calcitriol.Alexithymia, anxiety and depression in patients with psoriasis: a case-control studyMetabolic changes and serum ghrelin level in patients with psoriasis.Patient-reported outcomes and the association with clinical response in patients with active psoriatic arthritis treated with golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial.LC-MS metabolomics of psoriasis patients reveals disease severity-dependent increases in circulating amino acids that are ameliorated by anti-TNFα treatment.
P2860
Q24674877-E873BC56-7BD3-45F9-B378-0F9FA083C042Q24791176-E564A9C7-F86C-454B-B9B4-00DB20081290Q24791832-0A6153C3-C11C-4C18-BA96-B9FC33CF43D8Q24816472-22AC9A38-66F6-40F9-8183-4D827E9700D7Q27021322-1A47A776-948C-4E00-84D1-61F66FFEC7E9Q27691377-44A810E0-283B-490B-B0AA-AED2EAEE96FDQ28082927-8E682F8F-DB9A-4199-A561-B48039E364D0Q33252507-03D66E5F-3654-42BB-AD78-1EE48AD8F85FQ33358541-67FE43B3-B4FB-43D0-ABF4-3A698F8030E6Q33544881-243051DF-BE49-46E0-8585-B18DB6EA160EQ33631646-9812577B-A48D-422C-82BE-3ECBB88B707EQ33645853-1D9208F5-72ED-4103-97D8-367C7A262B3DQ33659249-5461763B-5687-4A93-9B7B-E1FC77E76E3EQ33673930-FEBE1663-5E00-4BEC-866E-696362E7EDA9Q33729774-769FAE98-2430-4C69-A923-B1806D731960Q33794292-8F21378A-58D0-4BC1-A2FF-1F25561A2696Q33800651-09595C30-5CCC-4CF3-B51B-88F27B418602Q33802843-30B0393A-D207-4567-83EB-D488F0FFDBDAQ33803222-4A1D4A5E-E645-4D9A-81AD-490DA8B7410BQ33826257-8295A03F-5C94-45B1-BDD8-6B365BCAEA9FQ33882485-DB98A8B5-79FC-41DD-91C5-3DF53152B139Q33884648-873F8A4E-A7FF-45BF-A171-3726980F5155Q33902313-70F8268C-10E7-4D18-8110-6FEE44041BF9Q33916770-F3E1FF57-E0CB-4EF0-9208-D71775FC9315Q33919359-9DD72671-D7BB-445C-87AB-C3D9BF9FD23EQ34071641-7AC5939D-9BE6-46FA-B367-207F38C373AEQ34112840-B1077623-9F0A-4074-80F9-200A9B1CE8B8Q34140480-ED7E90B4-FA80-4098-A68C-E7FFE3910DF5Q34153144-43B63DBD-FD82-4AE3-AEE0-5B9AED510F2BQ34174214-6332C9A8-2CD3-438B-B691-25AA2CCB835BQ34299257-98C7415E-33BA-4FAF-B2CD-E4365C7169CDQ34409690-6E1A5305-4DE1-447F-AB0B-540B7AC33896Q34485175-38CE090F-BBF6-4E19-A5FF-CDF975DAE18EQ34550167-9DC2AE50-B699-4465-9CEF-F9253B2EF643Q34613907-280D708C-48A2-4DFA-8E78-07B95EEACC4CQ34620250-F1F9BDCE-B67D-40AF-841B-BB9E681E3B6DQ34722040-D1BABA71-BE5E-45F7-9E39-7AA8394FB91FQ34798951-C24728AB-8CB9-4EC0-8F4B-4AEB8EDCC8C7Q34803148-6172B20E-528F-4AAA-87E0-B4366B3590E9Q34855603-415D99E1-1C82-47A3-A467-344B6A59310E
P2860
description
1978 nî lūn-bûn
@nan
1978 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
1978 թվականի հունվարին հրատարակված գիտական հոդված
@hy
1978年の論文
@ja
1978年論文
@yue
1978年論文
@zh-hant
1978年論文
@zh-hk
1978年論文
@zh-mo
1978年論文
@zh-tw
1978年论文
@wuu
name
Severe psoriasis--oral therapy with a new retinoid.
@ast
Severe psoriasis--oral therapy with a new retinoid.
@en
Severe psoriasis--oral therapy with a new retinoid.
@nl
type
label
Severe psoriasis--oral therapy with a new retinoid.
@ast
Severe psoriasis--oral therapy with a new retinoid.
@en
Severe psoriasis--oral therapy with a new retinoid.
@nl
prefLabel
Severe psoriasis--oral therapy with a new retinoid.
@ast
Severe psoriasis--oral therapy with a new retinoid.
@en
Severe psoriasis--oral therapy with a new retinoid.
@nl
P1433
P1476
Severe psoriasis--oral therapy with a new retinoid.
@en
P2093
Fredriksson T
Pettersson U
P304
P577
1978-01-01T00:00:00Z